Veterinary/Animal Vaccines Market Research Report - Forecast till 2027

Veterinary/Animal Vaccines Market Information: By Type (Livestock Vaccines, Porcine Vaccines), Technology (Live Attenuated Vaccines, Inactivated Vaccines), and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/1994-CR | May 2019 | Region: Global | 133 pages


Veterinary/Animal Vaccines Market Overview


The CAGR for the Veterinary/Animal Vaccines Market is expected to be 7.2% in 2025. The veterinary/animal vaccines market value is projected to be USD 11 billion in 2025. 


The important of veterinary vaccines can’t be understated or ignored. It’s these vaccines that make most farm animals stronger. It also prevents them from getting viruses and bacteria that can be dangerous and/or even deadly for humans if consumed. COVID-19 is a good example of this. It was transmitted from humans to bats when the Chinese ate meat from infected bats in their soups! 


COVID-19 analysis


COVID-19 is to the 21st century what the Bubonic Plague was to the 5th century and the Black Death was to the 14th century - a real destiny and game changer. COVID-19 was initially transmitted to humans from bats in China. It quickly spread across the world. Governments realized that this virus was dangerous and posing a real problem when some of the people who contracted it died. Many more who recovered either got it again or suffered real and long-term health issues.


The veterinary/animal vaccines market suffered immensely because pet owners and farmers were encouraged to keep their animals at home. They were advised against taking their pets to the vet to get strong and effective vaccines like the Pfizer veterinary vaccines. Growth in the veterinary/animal vaccines market is starting to pick up dramatically now that a vaccine for COVID-19 is being widely administered. Demand for animal vaccines is surging because livestock on farms around the world need these to remain healthy. 


Market dynamics


Drivers


As the middle classes around the world explode, so does the preference to keep pets. Most people keep cats and dogs as pets.. These pets need vaccines in order to stay healthy. This is one large driver of growth in the veterinary/animal vaccines market. 


Growing middle classes around the world means that the demand for meat consumption is rising dramatically around the world. This raises the importance of veterinary vaccines because farm animals need to be vaccinated before they are slaughtered for human consumption. This keeps the meat healthier and helps it last longer. It also keeps animals from developing dangerous bacteria, parasites, and viruses that can harm or even kill humans. In fact, according to the international veterinary vaccines and diagnostics conference 2006 the demand for various types of animal vaccines will increase dramatically in later years. 


Opportunities


There are many emerging opportunities in the veterinary/animal vaccines market. Many veterinary clinics are investing heavily in research and development to develop and market more advanced vaccines that will keep animals healthier and stronger and help them live longer. 


Vaccines for animals are also getting a strong boost from technological advancements. It’s advancements in technology that promise to make a new generation of stronger animal vaccines that are much more effective and last longer. 


Research and development will also allow vaccine manufacturers to develop and market hybrid vaccines. These will be much more effective, hence they will be extremely profitable. 


Restraints


All vaccines have side effects. Animal vaccines are no exception. This is a key restraint in the veterinary/animal vaccines market. Most farmers and pet owners are loath to get their animals vaccinated because they are all too aware of the side effects but they are not aware enough of the benefits of these vaccines. Most farmers don’t get their animals vaccinated for this reason. This is the case in developing nations. 


The animal vaccine market is also heavily regulated. This is another factor that’s holding back growth in the veterinary/animal vaccines market. 


Challenges


Some animal vaccines for some segments of animals are very expensive. This factor is a major challenge in the veterinary/animal vaccines market. Animal vaccine manufacturers will also have to find ways to better educate animal owners about the benefits of animal vaccines. 


Technology analysis


Merck is a major American player in the veterinary/animal vaccines market. It became an industry leader by creating a sustainable competitive advantage. Intensive investments in research and development have allowed it to do this. 


Segment overview


By type


The veterinary/animal vaccines market can be grouped into the following sub-segments by type:



  • Porcine Vaccines

  • Poultry Vaccine

  • Livestock Vaccine

    • Bovine Vaccines

    • Small Ruminant Vaccines



  • Companion Animal Vaccine

    • Canine Vaccine

    • Feline Vaccine



  • Aquaculture Vaccines

  • Other Animal Vaccines


The attenuated vaccines sub-segment held the highest market share last year because they do a better job of boosting animals’ immune systems than other vaccines do. Also, animals who get attenuated vaccines need fewer booster shots less often. Most booster vaccines are given to animals orally. This makes them less effective in strengthening the animals’ immune systems and keeping them healthier than vaccines that are given by injection. 


The companion animal vaccines are given to cats and dogs. Livestock vaccines tend to be given to farm animals. The livestock vaccine market had the highest market share in 2020. The reason was that these animals tend to be vaccinated more frequently and more often than companion animals. 


By disease


The veterinary/animal vaccines market can be grouped into the following sub-segments by disease:



  • Porcine

  • Poultry

  • Livestock

    • Bovine

    • Small Ruminant



  • Companion Animal

    • Canine

    • Feline



  • Aquaculture


By technology


The veterinary/animal vaccines market can be grouped into the following sub-segments by type:



  • Live Attenuated Vaccines

  • Inactivated Vaccines

  • Toxoid Vaccines

  • Recombinant Vaccines

  • Other Vaccines


Regional analysis


The veterinary/animal vaccines market can be divided into the following geographic regions:



  • North America

  • Asia-Pacific

  • The European Union


North America has the highest market share. The reason is that North Americans tend to have more pets than people in the rest of the world. This is especially true in America. People in the North American region also tend to eat more meat and dairy products than people who live in other parts of the world do. They also tend to drink more milk. All of these need to come from immunized animals to be considered safe for human consumption.


Americans and Canadians, especially, are much more aware of the benefits of animal vaccines than people in the rest of the world are.


The Asia-Pacific region is projected to have the highest CAGR for the years that this report covers. The reason is that more people in Asian nations are adopting cats and dogs as pets - the middle classes are growing and they want to mimic their Western counterparts. The Asia-Pacific region (especially those nations in East Asia) has seen a rise in the number of strange viruses that are transmitted to humans by animals. COVID-19 happens to be one of these.


Asian nations are also investing heavily in animal vaccines both through government efforts and through private enterprise. The result has been the development of animal vaccines that are more effective, stronger, and have more innovative uses. This is needed since meat consumption is rising dramatically throughout the Asia-Pacific region.


Competitive landscape


The veterinary/animal vaccines market is very competitive. There are many reasons for this. The first is that there is a lot of money to be made in veterinary/animal vaccines market. The second is that there are relatively few barriers to entry. This especially applies to veterinary vaccine suppliers. Companies are finding that they can survive and create a sustainable competitive advantage only if they invest in research and development to try to create newer generations of innovative animal vaccines that will be more effective, have more innovative uses, and will sell better!


Companies also find that they can stay competitive if they enter into strategic partnerships with other successful companies and/or if they merge with/acquire other successful companies.


Merck is an American company that has been very successful in the veterinary/animal vaccines market. It has managed to create a sustainable competitive advantage by investing heavily in research and development. This has allowed it to develop and market a new generation of effective vaccines which have put the company in a good market position.


List of companies



  • Zoetis (US)

  • Virbac SA (France)

  • Merck (US)

  • Phibro Animal Health Corporation (US)

  • Boehringer Ingelheim (Germany)

  • Ceva (France)

  • Elanco (US) 


Recent developments



  • Many key companies in the veterinary/animal vaccines market have stayed successful by entering into strategic partnerships with other successful companies. They have managed to develop a new vaccine for poultry (chicks to be exact). This is very effective so it has great revenue generation potential.

  • Big companies are partnering up to develop new aquaculture vaccines that will do a better job of protecting aquatic life from diseases.

  • Elanco acquired a new animal vaccine company as part of its expansion strategy


Report overview


The CAGR for the veterinary/animal vaccines market is 7.5%. The veterinary/animal vaccines market is projected to be worth USD 11 billion in 2025. The North American region has the largest market share but the Asia-Pacific region has the highest CAGR.




Report Scope:
Report Attribute/Metric Details
  Market Size   2025: USD 11 Billion
  CAGR   7.2% (2018-2025)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Technology, Region
  Geographies Covered   North America, Europe, Asia-Pacific, Rest of the World
  Key Vendors   Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)
  Key Market Opportunities

  • High development opportunities in the upcoming years
  • Technological developments
  •   Key Market Drivers

  • The increasing rate of pet adoption
  • Rising expenditure on the pet treatment
  • High consumption of meat


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    More technological advancement is leading to better and more innovative vaccines

    Zoetis (US), Virbac SA (France), Merck (US), Phibro Animal Health Corporation (US), Boehringer Ingelheim (Germany), Ceva (France), Elanco (US)

    1 Report Prologue

    2 Executive Summary

    3 Market Introduction

    3.1 Definition 18

    3.2 Scope of the Study 18

    3.3 Research Objective 18

    3.4 Assumptions & Limitations 18

    3.4.1 Assumptions 18

    3.4.2 Limitations 18

    3.5 Market Structure 19

    4 Research Methodology

    4.1 Research Process 21

    4.2 Primary Research 22

    4.3 Secondary Research 23

    4.4 Market Size Estimation 24

    4.5 Forecast Model 24

    5 Market Dynamics

    5.1 Introduction 26

    5.2 Drivers 27

    5.2.1 Increasing Number of Pet Owners 27

    5.2.2 Growing Livestock Population and Disease Outbreaks 27

    5.2.3 Advances in Technology underlying Veterinary Vaccines 27

    5.2.4 Various Initiatives by Several Government Agencies, Animal Associations, and Prominent Market Players 28

    5.3 Restraint 28

    5.3.1 High Storage Cost associated with Veterinary Vaccines 28

    5.4 Opportunity 28

    5.4.1 Rising Investments to Improve Animal Health 28

    6 Market Factor Analysis

    6.1 Porter’s Five Forces Model 30

    6.1.1 Bargaining Power of Suppliers 30

    6.1.2 Bargaining Power of Buyers 31

    6.1.3 Threat of New Entrants 31

    6.1.4 Threat of Substitutes 31

    6.1.5 Rivalry 31

    6.2 Supply Chain Analysis 31

    6.2.1 R&D and Development 32

    6.2.2 Manufacturing 32

    6.2.3 Distribution & Sales 32

    6.2.4 Post-Sales Monitoring 32

    7 Veterinary/Animal Vaccines Market, by Type

    7.1 Introduction 35

    7.1.1 Livestock Vaccines 37

    7.1.2 Porcine Vaccines 38

    7.1.3 Companion Animal Vaccines 38

    7.1.4 Poultry Vaccines 39

    7.1.5 Aquaculture Vaccines 39

    8 Veterinary/Animal Vaccines Market, by Technology

    8.1 Introduction 41

    8.1.1 Live Attenuated Vaccines 43

    8.1.2 Inactivated Vaccines 43

    8.1.3 Recombinant Vaccines 44

    8.1.4 Toxoid Vaccines 44

    9 Global Veterinary/Animal Vaccines Market, by Region

    9.1 Introduction 46

    9.2 Americas 48

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.2.1 North America 51

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.2.1.1 US 53

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.2.1.2 Canada 55

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.2.2 South America 57

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3 Europe 60

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1 Western Europe 63

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1.1 France 65

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1.2 Germany 67

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1.3 UK 69

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1.4 Spain 71

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1.5 Italy 73

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.1.6 Rest of Western Europe 75

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.3.2 Eastern Europe 77

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4 Asia-Pacific 80

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4.1 Japan 83

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4.2 China 85

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4.3 India 87

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4.4 Australia 89

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4.5 Republic of Korea 91

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.4.6 Rest of Asia-Pacific 93

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.5 Middle East and Africa 95

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.5.1 Middle East 98

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    9.5.2 Africa 100

    Veterinary/Animal Vaccines Market, by Type

    Veterinary/Animal Vaccines Market, by Technology

    10 Competitive Landscape

    10.1 Introduction 103

    11 Company Profiles

    11.1 Boehringer Ingelheim International GmbH 106

    11.1.1 Company Overview 106

    11.1.2 Financial Overview 106

    11.1.3 Products/Services Offered 107

    11.1.4 Key Developments 107

    11.1.5 SWOT Analysis 107

    11.1.6 Key Strategies 107

    11.2 Zoetis 108

    11.2.1 Company Overview 108

    11.2.2 Financial Overview 108

    11.2.3 Products/Services Offered 109

    11.2.4 Key Developments 109

    11.2.5 SWOT Analysis 110

    11.2.6 Key Strategies 110

    11.3 Ceva 111

    11.3.1 Company Overview 111

    11.3.2 Financial Overview 111

    11.3.3 Products/Services Offered 112

    11.3.4 Key Developments 112

    11.3.5 SWOT Analysis 113

    11.3.6 Key Strategies 113

    11.4 MSD & Co. Inc. 114

    11.4.1 Company Overview 114

    11.4.2 Financial Overview 114

    11.4.3 Products/Services Offered 115

    11.4.4 Key Developments 116

    11.4.5 SWOT Analysis 116

    11.4.6 Key Strategies 116

    11.5 Elanco 117

    11.5.1 Company Overview 117

    11.5.2 Financial Overview 117

    11.5.3 Products/Services Offered 118

    11.5.4 Key Developments 118

    11.5.5 SWOT Analysis 118

    11.5.6 Key Strategies 119

    11.6 Virbac 120

    11.6.1 Company Overview 120

    11.6.2 Financial Overview 120

    11.6.3 Products/Services Offered 121

    11.6.4 Key Developments 121

    11.6.5 SWOT Analysis 121

    11.6.6 Key Strategies 121

    11.7 Phibro Animal Health Corporation. 122

    11.7.1 Company Overview 122

    11.7.2 Financial Overview 122

    11.7.3 Products/Services Offered 123

    11.7.4 Key Developments 123

    11.7.5 SWOT Analysis 123

    11.7.6 Key Strategies 123

    11.8 Hipra 124

    11.8.1 Company Overview 124

    11.8.2 Financial Overview 124

    11.8.3 Products/Services Offered 124

    11.8.4 Key Developments 125

    11.8.5 SWOT Analysis 125

    11.8.6 Key Strategies 125

    11.9 IDT Biologika GmbH 126

    11.9.1 Company Overview 126

    11.9.2 Financial Overview 126

    11.9.3 Products/Services Offered 126

    11.9.4 Key Developments 126

    11.9.5 SWOT Analysis 127

    11.9.6 Key Strategies 127

    11.10 Biogenesis Bago SA 128

    11.10.1 Company Overview 128

    11.10.2 Financial Overview 128

    11.10.3 Products/Services Offered 128

    11.10.4 Key Developments 128

    11.10.5 SWOT Analysis 129

    11.10.6 Key Strategies 129

    12 Appendix

    12.1 Discussion Blue Print 131

    13 List of Tables

    TABLE 1 MARKET SYNOPSIS 16

    TABLE 2 PRIMARY INTERVIEWS 21

    TABLE 3 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 36

    TABLE 4 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 36

    TABLE 5 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 37

    TABLE 6 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY REGION, 2020–2027 (USD MILLION) 37

    TABLE 7 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR PORCINE VACCINES, BY REGION, 2020–2027 (USD MILLION) 38

    TABLE 8 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY REGION, 2020–2027

    (USD MILLION) 38

    TABLE 9 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR POULTRY VACCINES, BY REGION, 2020–2027 (USD MILLION) 39

    TABLE 10 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR AQUACULTURE VACCINES, BY REGION, 2020–2027 (USD MILLION) 39

    TABLE 11 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 42

    TABLE 12 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR LIVE ATTENUATED VACCINES, BY REGION, 2020–2027 (USD MILLION) 43

    TABLE 13 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR INACTIVATED VACCINES, BY REGION, 2020–2027 (USD MILLION) 43

    TABLE 14 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR RECOMBINANT VACCINES, BY REGION, 2020–2027 (USD MILLION) 44

    TABLE 15 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FOR TOXOID VACCINES, BY REGION, 2020–2027 (USD MILLION) 44

    TABLE 16 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 47

    TABLE 17 AMERICAS: VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 48

    TABLE 18 AMERICAS: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 49

    TABLE 19 AMERICAS: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 49

    TABLE 20 AMERICAS: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 50

    TABLE 21 AMERICAS: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 50

    TABLE 22 NORTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 51

    TABLE 23 NORTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

    TABLE 24 NORTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 52

    TABLE 25 NORTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 52

    TABLE 26 NORTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 53

    TABLE 27 US: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

    TABLE 28 US: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 54

    TABLE 29 US: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 54

    TABLE 30 US: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 55

    TABLE 31 CANADA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

    TABLE 32 CANADA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 56

    TABLE 33 CANADA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 56

    TABLE 34 CANADA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 57

    TABLE 35 SOUTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

    TABLE 36 SOUTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 58

    TABLE 37 SOUTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 58

    TABLE 38 SOUTH AMERICA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 59

    TABLE 39 EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 60

    TABLE 40 EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

    TABLE 41 EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 61

    TABLE 42 EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 62

    TABLE 43 EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 62

    TABLE 44 WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63

    TABLE 45 WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 63

    TABLE 46 WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 64

    TABLE 47 WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 64

    TABLE 48 WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 65

    TABLE 49 FRANCE: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

    TABLE 50 FRANCE: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 66

    TABLE 51 FRANCE: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 66

    TABLE 52 FRANCE: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 67

    TABLE 53 GERMANY: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

    TABLE 54 GERMANY: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 68

    TABLE 55 GERMANY: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 68

    TABLE 56 GERMANY: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 69

    TABLE 57 UK: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

    TABLE 58 UK: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 70

    TABLE 59 UK: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 70

    TABLE 60 UK: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 71

    TABLE 61 SPAIN: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

    TABLE 62 SPAIN: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 72

    TABLE 63 SPAIN: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 72

    TABLE 64 SPAIN: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 73

    TABLE 65 ITALY: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

    TABLE 66 ITALY: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 74

    TABLE 67 ITALY: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 74

    TABLE 68 ITALY: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 75

    TABLE 69 REST OF WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

    TABLE 70 REST OF WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 76

    TABLE 71 REST OF WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 76

    TABLE 72 REST OF WESTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 77

    TABLE 73 EASTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

    TABLE 74 EASTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 78

    TABLE 75 EASTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 78

    TABLE 76 EASTERN EUROPE: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 79

    TABLE 77 ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80

    TABLE 78 ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

    TABLE 79 ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 81

    TABLE 80 ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 82

    TABLE 81 ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 82

    TABLE 82 JAPAN: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

    TABLE 83 JAPAN: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 83

    TABLE 84 JAPAN: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 84

    TABLE 85 JAPAN: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 84

    TABLE 86 CHINA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 87 CHINA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 88 CHINA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 86

    TABLE 89 CHINA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 86

    TABLE 90 INDIA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

    TABLE 91 INDIA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 87

    TABLE 92 INDIA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 88

    TABLE 93 INDIA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 88

    TABLE 94 AUSTRALIA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

    TABLE 95 AUSTRALIA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 89

    TABLE 96 AUSTRALIA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 90

    TABLE 97 AUSTRALIA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 90

    TABLE 98 REPUBLIC OF KOREA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

    TABLE 99 REPUBLIC OF KOREA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 91

    TABLE 100 REPUBLIC OF KOREA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 92

    TABLE 101 REPUBLIC OF KOREA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 92

    TABLE 102 REST OF ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

    TABLE 103 REST OF ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 93

    TABLE 104 REST OF ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 94

    TABLE 105 REST OF ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 94

    TABLE 106 MIDDLE EAST AND AFRICA: VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2020–2027 (USD MILLION) 95

    TABLE 107 MIDDLE EAST AND AFRICA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 96

    TABLE 108 MIDDLE EAST AND AFRICA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 96

    TABLE 109 MIDDLE EAST AND AFRICA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 97

    TABLE 110 MIDDLE EAST AND AFRICA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 97

    TABLE 111 MIDDLE EAST: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 98

    TABLE 112 MIDDLE EAST: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 98

    TABLE 113 MIDDLE EAST: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027

    (USD MILLION) 99

    TABLE 114 MIDDLE EAST: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 99

    TABLE 115 AFRICA: VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020–2027 (USD MILLION) 100

    TABLE 116 AFRICA: VETERINARY/ANIMAL VACCINES MARKET, FOR LIVESTOCK VACCINES, BY TYPE, 2020–2027 (USD MILLION) 100

    TABLE 117 AFRICA: VETERINARY/ANIMAL VACCINES MARKET, FOR COMPANION ANIMAL VACCINES, BY TYPE, 2020–2027 (USD MILLION) 101

    TABLE 118 AFRICA: VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 101

    14 List of Figures

    FIGURE 1 RESEARCH PROCESS 21

    FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH 24

    FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL VETERINARY/ANIMAL VACCINES MARKET 26

    FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL VETERINARY/ANIMAL VACCINES MARKET 30

    FIGURE 5 SUPPLY CHAIN: GLOBAL VETERINARY/ANIMAL VACCINES MARKET 32

    FIGURE 6 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020 (% SHARE) 35

    FIGURE 7 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020 & 2027 35

    FIGURE 8 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY,2020 (% SHARE) 41

    FIGURE 9 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TYPE, 2020 & 2027 42

    FIGURE 10 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2020 (% SHARE) 46

    FIGURE 11 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY REGION, 2020 & 2027 (USD MILLION) 46

    FIGURE 12 AMERICAS: VETERINARY/ANIMAL VACCINES MARKET SHARE, BY REGION, 2020 (% SHARE) 48

    FIGURE 13 EUROPE: VETERINARY/ANIMAL VACCINES MARKET SHARE, BY REGION, 2020 (% SHARE) 60

    FIGURE 14 ASIA-PACIFIC: VETERINARY/ANIMAL VACCINES MARKET SHARE, BY COUNTRY, 2020 (% SHARE) 80

    FIGURE 15 MIDDLE EAST AND AFRICA: VETERINARY/ANIMAL VACCINES MARKET SHARE, BY REGION, 2020 (% SHARE) 95

    FIGURE 16 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, MARKET SHARE ANALYSIS 2020 (%) 103